PeptideStack
5.2kquestions
20kanswers
220users

Does early satiety at week eight of semaglutide usually resolve without a dose change?

Asked 1 Apr 2024Modified 2.0 years agoViewed 46k times
40

The specifics, since they change the answer: early satiety · eight · semaglutide.

Everything I have found on this is either a forum aside or a product page, neither of which I trust.

I am comfortable with the arithmetic; what I am missing is the procedural detail around it.

What is the correct sequence, and where is the step that people usually skip?

gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
shareeditfollowflag
AZ
askedahmed_zerouali15k171 Apr 2024
3Same situation here, so I will follow this one. – tandem_gradient 4 months ago
4How long since the last dose increase? The timing is most of the diagnosis here. – forty_two_c 6 months ago
add a comment

5 Answers

Accepted answer first, then by votes
130

Accepted answer

Week 8 is day 56: on a four-week ladder that is week 4 of dose step 2, and — at the seven-day half-life this class runs on — 8 half-lives in. Steady state is about five half-lives, so day 35 is where the concentration stops climbing on its own. Day 56 is 3 weeks past it, which means the level is no longer the variable. That distinction is most of the question: at week 4 of a step, an effect that is still accumulating is indistinguishable from one that is not resolving unless you know which side of day 35 you are on. Early satiety is the mechanism rather than a side effect of it — delayed gastric emptying is the intended pharmacology — so the question the week number helps with is whether it is proportionate, not whether it is expected. Dose decisions are made under supervision, and nothing here is medical advice.

Start with which symptom predominates, because the management diverges sharply even though the mechanism does not.

Symptom prevalence in trials, broadly: nausea a quarter to a half, diarrhoea and constipation each roughly ten to twenty per cent, vomiting rather less, with all rates rising with dose.

Gastrointestinal adverse events, indicative pooled rates

EventActive armPlacebo armTiming
Nausea40–45 %15–20 %Peaks 1–2 wk after each step
Vomiting15–25 %5–8 %Follows nausea
Diarrhoea20–30 %10–15 %Early, variable
Constipation20–25 %8–12 %Later onset, persistent
Discontinuation for GI events4–7 %1–2 %Mostly during escalation

Ranges span agents and doses; read the specific prescribing information for a specific figure.

Concretely, fat is the macronutrient that slows emptying most on its own, so a high-fat meal on top of pharmacologically delayed emptying is the combination that produces the worst episodes.

Dietary fat slowing gastric emptying is basic gastrointestinal physiology and independent of any drug effect.

Nothing here is medical advice.

Smaller meals, less fat, fluids between rather than with. In that order.

edited 24 Jul 2024 by Dr_Nadia_Farsi — added the citation requested in comments

shareimprove this answerflag
DF
answered · acceptedDr_Nadia_Farsi104k24713 Jul 2024
Adding a vote because this deserves more of them. – Dr_Nadia_Farsi 8 months ago
I would add a sentence about when to stop managing it and start seeing someone. – teodora_ilic 6 days ago
add a comment
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
50

The short version: dose-related, escalation-concentrated, mostly attenuating except for constipation, and manageable by titration pace more than anything else.

The practical hierarchy of interventions: slow the titration, reduce meal size, reduce fat, separate fluids from meals, and only then consider symptomatic treatment.

More usefully, discontinuation for gastrointestinal effects in the trials runs in the low single-figure percentages, which means the great majority of people who experience these effects continue.

Research-use compounds are not approved for human use.

Most people who report these effects continue. The discontinuation rate is low.

shareimprove this answerflag
TA
answeredtess_amankwah22k2725 Jul 2024
Adding for future readers: fluids between meals rather than with them made a real difference. – fib4_reader 5 months ago
add a comment
40

Answering this needs the titration history, because going faster than the schedule is the single largest modifiable factor.

Anticipating a slower-than-label titration from the start is a legitimate approach and costs only time, since the exposure ceiling is the same.

Put another way, symptoms that appear for the first time at a stable dose after months are not the ordinary pattern and warrant looking for another explanation.

Four-weekly titration intervals in the licensed schedules were selected to allow tolerance between escalations.

The caveat is that severe persistent symptoms, particularly with dehydration or severe pain, are clinical and not a matter of waiting them out.

New symptoms at a stable dose after months need a different explanation.

shareimprove this answerflag
DV
answeredDr_Ilse_Vandenberg113k2487 Apr 2024
6This is the first explanation of the timing pattern that has actually made sense to me. – loss_on_drying 6 months ago
7The distinction between escalation-related and steady-state is the useful part. – stopper_core 8 months ago
add a comment
32

Diarrhoea and constipation both occur, which surprises people until they consider how many mechanisms are involved.

Gastric emptying of a solid meal can be delayed substantially at initiation. The effect is largest early and attenuates over weeks for the long-acting agents, which is the mechanistic basis for the titration schedule.

Trial-reported incidence and discontinuation rates for gastrointestinal effects are published per agent and per dose and are the appropriate figures to quote.

Slow the titration first. It is the intervention with the best evidence and the lowest cost.

shareimprove this answerflag
DO
answeredDr_Lena_Ostrowska38k2718 Apr 2024
29

The relevant physiology is that gastric emptying slows substantially and then partially normalises with continued exposure at a stable dose.

Reflux occurs because a slower-emptying stomach retains volume for longer against a lower oesophageal sphincter that has not changed. Smaller meals and not lying down within a few hours are the direct responses.

Gastric emptying studies in this class quantify the delay directly and document its attenuation with continued exposure to the long-acting agents.

Everything except constipation attenuates. Plan differently for that one.

shareimprove this answerflag
SD
answeredsunniva_dahl22k2730 May 2024
5Thank you — knowing this was expected rather than alarming was most of what I needed. – ines_brandt 2 months ago
6This should be linked from the help pages. – valentina_rossi 4 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.